Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
543 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015', provides an overview of the Type 1 Diabetes (Juvenile Diabetes)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Type 1 Diabetes (Juvenile Diabetes) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Type 1 Diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Type 1 Diabetes (Juvenile Diabetes) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Type 1 Diabetes (Juvenile Diabetes) Overview 8 Therapeutics Development 9 Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies 11 Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes 21 Type 1 Diabetes (Juvenile Diabetes) - Pipeline Products Glance 24 Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies 27 Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes 39 Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 41 Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 134 Drug Profiles 146 Type 1 Diabetes (Juvenile Diabetes) - Recent Pipeline Updates 407 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 511 Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 519 Appendix 521
List of Tables
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2015 30 Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis, H1 2015 31 Number of Products under Development by Companies, H1 2015 33 Number of Products under Development by Companies, H1 2015 (Contd..1) 34 Number of Products under Development by Companies, H1 2015 (Contd..2) 35 Number of Products under Development by Companies, H1 2015 (Contd..3) 36 Number of Products under Development by Companies, H1 2015 (Contd..4) 37 Number of Products under Development by Companies, H1 2015 (Contd..5) 38 Number of Products under Development by Companies, H1 2015 (Contd..6) 39 Number of Products under Development by Companies, H1 2015 (Contd..7) 40 Number of Products under Development by Companies, H1 2015 (Contd..8) 41 Number of Products under Investigation by Universities/Institutes, H1 2015 43 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44 Comparative Analysis by Late Stage Development, H1 2015 45 Comparative Analysis by Clinical Stage Development, H1 2015 46 Comparative Analysis by Early Stage Development, H1 2015 47 Products under Development by Companies, H1 2015 48 Products under Development by Companies, H1 2015 (Contd..1) 49 Products under Development by Companies, H1 2015 (Contd..2) 50 Products under Development by Companies, H1 2015 (Contd..3) 51 Products under Development by Companies, H1 2015 (Contd..4) 52 Products under Development by Companies, H1 2015 (Contd..5) 53 Products under Development by Companies, H1 2015 (Contd..6) 54 Products under Development by Companies, H1 2015 (Contd..7) 55 Products under Development by Companies, H1 2015 (Contd..8) 56 Products under Development by Companies, H1 2015 (Contd..9) 57 Products under Development by Companies, H1 2015 (Contd..10) 58 Products under Development by Companies, H1 2015 (Contd..11) 59 Products under Investigation by Universities/Institutes, H1 2015 60 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 61 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by 4SC AG, H1 2015 62 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ActogeniX NV, H1 2015 63 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia, H1 2015 64 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AiCuris GmbH & Co. KG, H1 2015 65 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 66 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ambrx, Inc., H1 2015 67 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by American Gene Technologies International Inc., H1 2015 68 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AntriaBio, Inc., H1 2015 69 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Argos Therapeutics, Inc., H1 2015 70 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Artery Therapeutics, Inc., H1 2015 71 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by AstraZeneca PLC, H1 2015 72 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Axxam SpA, H1 2015 73 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Bayhill Therapeutics, Inc., H1 2015 74 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Beta-Cell NV, H1 2015 75 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biocon Limited, H1 2015 76 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biodel Inc., H1 2015 77 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Biogenomics Limited, H1 2015 78 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioLineRx, Ltd., H1 2015 79 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by BioTherapeutics Inc., H1 2015 80 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Boehringer Ingelheim GmbH, H1 2015 81 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Carlina Technologies SAS, H1 2015 82 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cellectis S.A., H1 2015 83 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Compugen Ltd., H1 2015 84 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Cortendo AB, H1 2015 85 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by CTI BioPharma Corp., H1 2015 86 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 87 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diabetology Limited, H1 2015 88 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DiaMedica Inc., H1 2015 89 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Diasome Pharmaceuticals, Inc., H1 2015 90 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 91 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by DoNatur GmbH, H1 2015 92 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Effimune SAS, H1 2015 93 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Eli Lilly and Company, H1 2015 94 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by EpiVax, Inc., H1 2015 95 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Evotec AG, H1 2015 96 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Extrawell Pharmaceutical Holdings Limited, H1 2015 97 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GeNeuro SA, H1 2015 98 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Gilead Sciences, Inc., H1 2015 99 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by GlaxoSmithKline plc, H1 2015 100 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Grifols, S.A., H1 2015 101 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Halozyme Therapeutics, Inc., H1 2015 102 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 103 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Hyperion Therapeutics, Inc., H1 2015 104 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Iltoo Pharma, H1 2015 105 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Immunocore Limited, H1 2015 106 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Intrexon Corporation, H1 2015 107 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Islet Sciences, Inc., H1 2015 108 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Johnson & Johnson, H1 2015 109 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kamada Ltd., H1 2015 110 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 111 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kineta, Inc., H1 2015 112 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 113 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2015 114 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 115 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MacroGenics, Inc., H1 2015 116 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Medestea Research & Production S.p.A., H1 2015 117 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MedImmune, LLC, H1 2015 118 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck & Co., Inc., H1 2015 119 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Merck KGaA, H1 2015 120 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Meridigen Biotech Co., Ltd., H1 2015 121 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mertiva AB, H1 2015 122 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by MidaSol Therapeutics LP, H1 2015 123 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 124 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NeoStem, Inc., H1 2015 125 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by NGM Biopharmaceuticals, Inc., H1 2015 126 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Novo Nordisk A/S, H1 2015 127 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Noxxon Pharma AG, H1 2015 128 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 129 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Opexa Therapeutics, Inc., H1 2015 130 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Oramed Pharmaceuticals, Inc., H1 2015 131 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Orgenesis, Inc., H1 2015 132 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015 133 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Pfizer Inc., H1 2015 134 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaCyte Biotech, Inc., H1 2015 135 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by PharmaIN Corporation, H1 2015 136 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Progen Pharmaceuticals Limited, H1 2015 137 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Prometheon Pharma, LLC, H1 2015 138 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Provid Pharmaceuticals, Inc., H1 2015 139 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by RedHill Biopharma Ltd., H1 2015 140 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by REGiMMUNE Corporation, H1 2015 141 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Sanofi, H1 2015 142 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by SEKRIS Biomedical, Inc., H1 2015 143 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Selecta Biosciences, Inc., H1 2015 144 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Shreya Life Sciences Pvt. Ltd., H1 2015 145 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Therapix Biosciences Ltd, H1 2015 146 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Thermalin Diabetes, LLC, H1 2015 147 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Toleranzia AB, H1 2015 148 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Transgene Biotek Limited, H1 2015 149 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Uni-Bio Science Group Ltd., H1 2015 150 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ViaCyte, Inc., H1 2015 151 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Visionary Pharmaceuticals, Inc., H1 2015 152 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by X-BODY BioSciences, Inc., H1 2015 153 Type 1 Diabetes (Juvenile Diabetes) - Pipeline by XOMA Corporation, H1 2015 154 Assessment by Monotherapy Products, H1 2015 155 Assessment by Combination Products, H1 2015 156 Number of Products by Stage and Target, H1 2015 158 Number of Products by Stage and Mechanism of Action, H1 2015 161 Number of Products by Stage and Route of Administration, H1 2015 164 Number of Products by Stage and Molecule Type, H1 2015 166 Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Recent Pipeline Updates, H1 2015 428 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2015 532 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..1), H1 2015 533 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..2), H1 2015 534 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..3), H1 2015 535 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..4), H1 2015 536 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..5), H1 2015 537 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..6), H1 2015 538 Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects (Contd..7), H1 2015 539 Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2015 540 Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products (Contd..1), H1 2015 541
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
